Skip to main content

IBMT19101 / KTE-C19-104 / KITE Zuma 4 / Kristen O'Dwyer

Research Question:
Is the drug KTE-X19 safe and effective in treating acute lymphoblastic leukemia (ALL) or B-cell non-Hodgkin lymphoma (NHL)?

Basic Study Information

The primary objectives of this study are to evaluate the safety and efficacy of brexucabtagene autoleucel (KTE-X19) in pediatric and adolescent participants with relapsed/refractory (r/r) B-precursor acute lymphoblastic leukemia (ALL) or relapsed or refractory (r/r) B-cell non-Hodgkin lymphoma (NHL). As of October 2022, no further patients with acute B-cell Acute Lymphoblastic Leukemia (ALL) will be asked to join the study. The study remains open for recruitment for patients that have B-cell Non Hodgkin Lymphoma (NHL).

Location: University of Rochester Medical Center
Study Reference #: IBMT19101

Lead Researcher (Principal Investigator)

Lead Researcher:  Kristen O'Dwyer

Study Contact Information

Study Contact: Clinical Trials Office
Study Location: Wilmot Cancer Institute, University of Rochester Medical Center
Study Email:

Additional Study Details

Return to Search